Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from China Bozza Development Holdings Limited ( (HK:1069) ).
China Health Technology Group Holding Company Limited has announced the appointment of Mr. Li Zhiliang as the CEO of its subsidiary, Genmao (Shenzhen) Biotechnology Co., Ltd. Mr. Li brings over 22 years of experience in the acer truncatum industry and has been involved in national projects and standards related to acer truncatum. His appointment is expected to enhance the company’s technological capabilities and brand influence, contributing to long-term shareholder value.
More about China Bozza Development Holdings Limited
China Health Technology Group Holding Company Limited operates in the biotechnology sector, with a focus on the development of the entire industrial chain of acer truncatum, particularly in the functional food and oil market.
YTD Price Performance: -2.50%
Average Trading Volume: 1,760,747
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$34.37M
Find detailed analytics on 1069 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue